midazolam   Click here for help

GtoPdb Ligand ID: 3342

Synonyms: Buccolam® | Dormicum® | Nayzilam® | USL261 (nasal spray formulation) [1] | Versed®
Approved drug PDB Ligand
midazolam is an approved drug (FDA (2000), EMA (2011))
Compound class: Synthetic organic
Comment: Midazolam is a benzodiazepine class sedative drug.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 1
Topological polar surface area 29.66
Molecular weight 325.08
XLogP 4.57
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Clc1ccc2c(c1)C(=NCc1n2c(C)nc1)c1ccccc1F
Isomeric SMILES Clc1ccc2c(c1)C(=NCc1n2c(C)nc1)c1ccccc1F
InChI InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3
InChI Key DDLIGBOFAVUZHB-UHFFFAOYSA-N
References
1. Bancke LL, Dworak HA, Rodvold KA, Halvorsen MB, Gidal BE. (2015)
Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers.
Epilepsia, 56 (11): 1723-31. [PMID:26332539]
2. Detyniecki K, Van Ess PJ, Sequeira DJ, Wheless JW, Meng TC, Pullman WE. (2019)
Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters-a randomized, double-blind, placebo-controlled trial.
Epilepsia, 60 (9): 1797-1808. [PMID:31140596]
3. Drummond AH, Hughes PJ, Ruiz-Larrea F, Joels LA. (1989)
Use of receptor antagonist in elucidating the mechanism of action of TRH in GH3 cells.
Ann N Y Acad Sci, 553: 197-204. [PMID:2566295]
4. Waugh DJ, Gaivin RJ, Damron DS, Murray PA, Perez DM. (1999)
Binding, partial agonism, and potentiation of alpha(1)-adrenergic receptor function by benzodiazepines: A potential site of allosteric modulation.
J Pharmacol Exp Ther, 291 (3): 1164-71. [PMID:10565838]
5. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA. (2002)
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Drug Metab Dispos, 30 (8): 883-91. [PMID:12124305]